CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers

Deregulation of the cell cycle machinery is a hallmark of cancer. While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen receptor-positive breast cancer, two major clinical challenges remain: (i) adverse events leading to therapy discontinuation and (ii) lack of reliab...

Descripción completa

Detalles Bibliográficos
Autores principales: Vijayaraghavan, Smruthi, Karakas, Cansu, Doostan, Iman, Chen, Xian, Bui, Tuyen, Yi, Min, Raghavendra, Akshara S., Zhao, Yang, Bashour, Sami I., Ibrahim, Nuhad K., Karuturi, Meghan, Wang, Jing, Winkler, Jeffrey D., Amaravadi, Ravi K., Hunt, Kelly K., Tripathy, Debu, Keyomarsi, Khandan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490269/
https://www.ncbi.nlm.nih.gov/pubmed/28653662
http://dx.doi.org/10.1038/ncomms15916

Ejemplares similares

Ejemplares similares